Shilpa Medicare launches branded generic anticancer drug Dasatinib

Shilpa Medicare Limited has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name 'DASASHIL'.

DASASHIL is first branded generic anticancer drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of chronic myeloid leukaemia (CML).

Current, monthly therapy cost of innovator is approximately 1.65 lacs. With the launch of DASASHIL, monthly cost of treatment will be reduced drastically to Rs. 6440.

DASAHIL will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability.
The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.

Today, there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by DASASHIL tablets.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types